Trends & Business
LactoSpore probiotic from Sabinsa granted new patent for depression symptoms in IBS patients
December 24th 2019Sabinsa (East Windsor, NJ) has been granted U.S. patent US10166261 for the administration of Bacillus coagulans MTCC 5856 (LactoSpore) at a dose of 2 billion CFU per day as a way to manage dementia and dementia-related sleep disorders, presented as symptoms of major depressive disorder, in humans with IBS.